Screen Shot 2021-07-29 at 6.27.38 PM.png

Alpine BioTherapeutics is developing the next generation stem cell-based therapy to treat blindness. The mission is to create a stem cell-based therapy to preserve and restore eyesight in patients afflicted by dry age-related macular degeneration (dry-AMD) and retinitis pigmentosa (RP). Their pilot animal study on biodistribution and tolerability of the lead product ABC-101 has been completed, with results indicating that the therapeutic lead is well tolerable and safely confined.